Aquestive Therapeutics (NASDAQ:AQST) Receives Market Outperform Rating from JMP Securities

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “market outperform” rating restated by research analysts at JMP Securities in a research note issued on Tuesday, Benzinga reports. They presently have a $9.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 81.09% from the stock’s previous close.

Several other research firms have also issued reports on AQST. Leerink Partners reaffirmed an “outperform” rating and issued a $12.00 target price (up from $10.00) on shares of Aquestive Therapeutics in a report on Monday, September 30th. HC Wainwright upped their target price on Aquestive Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, September 30th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $8.67.

Aquestive Therapeutics Stock Performance

AQST traded up $0.12 during midday trading on Tuesday, reaching $4.97. 696,209 shares of the company were exchanged, compared to its average volume of 1,786,051. The company’s fifty day moving average price is $4.38 and its 200 day moving average price is $3.67. The company has a market cap of $452.46 million, a price-to-earnings ratio of -11.83 and a beta of 2.85. Aquestive Therapeutics has a one year low of $1.29 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the firm posted ($0.10) earnings per share. As a group, sell-side analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics during the second quarter worth $27,000. SG Americas Securities LLC purchased a new stake in shares of Aquestive Therapeutics during the first quarter worth $54,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Aquestive Therapeutics during the second quarter worth $76,000. Financial Advocates Investment Management lifted its position in shares of Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.